Posted by Michael Wonder on 29 Jun 2021
Chiasma announces submission of marketing authorisation application for Mycapssa to the European Medicines Agency
28 June 2021 - Submission supported by previously announced data from Phase 3 MPOWERED trial.
Chiasma today announced that it has submitted a marketing authorisation application to the EMA seeking approval of Mycapssa (oral octreotide capsules) as a maintenance therapy for adults with acromegaly.
